Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

BUY
$0.15 - $0.27 $6,370 - $11,466
42,468 Added 113.48%
79,892 $18,000
Q1 2023

May 01, 2023

SELL
$0.13 - $0.19 $1,883 - $2,753
-14,491 Reduced 27.91%
37,424 $6,000
Q4 2022

Feb 15, 2023

SELL
$0.11 - $0.16 $4,418 - $6,427
-40,170 Reduced 43.62%
51,915 $6,000
Q3 2022

Nov 07, 2022

BUY
$0.15 - $2.1 $11,410 - $159,751
76,072 Added 475.06%
92,085 $14,000
Q2 2022

Aug 09, 2022

BUY
$1.22 - $1.95 $19,535 - $31,225
16,013 New
16,013 $26,000
Q1 2022

May 17, 2022

SELL
$1.15 - $1.97 $14,192 - $24,311
-12,341 Closed
0 $0
Q4 2021

Feb 17, 2022

SELL
$1.92 - $2.53 $5,677 - $7,481
-2,957 Reduced 19.33%
12,341 $24,000
Q3 2021

Nov 12, 2021

SELL
$1.94 - $2.55 $47,180 - $62,015
-24,320 Reduced 61.39%
15,298 $31,000
Q2 2021

Sep 17, 2021

BUY
$1.69 - $2.67 $66,954 - $105,780
39,618 New
39,618 $95,000
Q4 2020

Feb 24, 2021

SELL
$1.07 - $2.0 $59,027 - $110,332
-55,166 Closed
0 $0
Q3 2020

Dec 11, 2020

BUY
$1.11 - $1.4 $39,700 - $50,072
35,766 Added 184.36%
55,166 $67,000
Q2 2020

Aug 07, 2020

BUY
$1.12 - $1.63 $21,728 - $31,621
19,400 New
19,400 $25,000
Q4 2018

Jan 16, 2019

SELL
$0.6 - $1.72 $7,393 - $21,195
-12,323 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$1.55 - $2.17 $21,813 - $30,538
-14,073 Reduced 53.31%
12,323 $20,000
Q2 2018

Jul 30, 2018

SELL
$2.05 - $3.0 $23,392 - $34,233
-11,411 Reduced 30.18%
26,396 $58,000
Q2 2018

Jul 30, 2018

SELL
$2.05 - $3.0 $62,350 - $91,245
-30,415 Reduced 44.58%
37,807 $83,000
Q1 2018

May 14, 2018

BUY
$2.27 - $8.5 $154,863 - $579,887
68,222 New
68,222 $157,000

Others Institutions Holding VBLT

About Vascular Biogenics Ltd.


  • Ticker VBLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,348,896
  • Description
  • Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antib...
More about VBLT
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.